Shelley B Thunen sold $1.6M of RXST
Chief Financial Officer at RxSight, Inc.. 40,000 shares at an average of $39.33, traded Dec 15, 2023, filed Dec 18, 2023.
Score components
- +22RoleCFO
- +25Trade size$1.6M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001209191-23-059041, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 15, 2023 | MOption exercise Common Stock10b5-1 | +20,000 | $15.60 | $312k | 22,291 | Dec 18, 2023 |
| Dec 15, 2023 | SOpen-market sale Common Stock10b5-1 | -20,000 | $39.35 | $787k | 2,291 | Dec 18, 2023 |
| Dec 15, 2023 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -10,000 | $39.31 | $393k | 38,402 | Dec 18, 2023 |
| Dec 15, 2023 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -10,000 | $39.32 | $393k | 28,402 | Dec 18, 2023 |
| Dec 15, 2023 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 76,805 | Dec 18, 2023 |
Related signals
Other insiders at RxSight, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | RxSight, Inc. | Ilya Goldshleger Chief Operating Officer | $14k 2,041 shares | -2% | |
| 21Weak | RxSight, Inc. | Ronald M Kurtz MD Chief Medical Officer | $35k 5,100 shares | -7% | |
| 15Weak | RxSight, Inc. | Eric Weinberg See remarks | $14k 2,041 shares | -1% | |
| 34Weak | RxSight, Inc. | Mark Wilterding Chief Financial Officer | $54k 7,765 shares | -24% | |
| 12Weak | RxSight, Inc. | Tamara Fountain director | $180k 7,000 shares | -22% | |
| 38Weak | RXSTbuy RxSight, Inc. | Jesse Anderson Corley director | $100k 3,210 shares | - | |
| 0Weak | RxSight, Inc. | Ilya Goldshleger See remarks | $143k 3,105 shares | -7% | |
| 7Weak | RxSight, Inc. | Ilya Goldshleger See remarks | $282k 6,200 shares | -14% | |
| 24Weak | RxSight, Inc. | Shweta Maniar director | $174k 3,782 shares | -26% | |
| 8Weak | RxSight, Inc. | Ilya Goldshleger See remarks | $364k 7,975 shares | -17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.